The European Patent Office has issued a decision to grant a patent to the company MolMed on the therapeutic use of the experimental anti-cancer drug NGR-hTNF at low doses. The granting of the patent will be October 2, 2013. The drug is at the core of an extremely broad clinical development program that includes studies of both Phase III and Phase II in colon, lung, liver and ovarian cancers, malignant pleural mesothelioma and soft tissue sarcoma. The administration of low doses of this drug reduces extremely the risk of toxicity.